Browse IL10

Summary
SymbolIL10
Nameinterleukin 10
Aliases CSIF; IL10A; IL-10; cytokine synthesis inhibitory factor; T-cell growth inhibitory factor; GVHDS; IL-10A; In ......
Chromosomal Location1q31-q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted.
Domain PF00726 Interleukin 10
Function

Inhibits the synthesis of a number of cytokines, including IFN-gamma, IL-2, IL-3, TNF and GM-CSF produced by activated macrophages and by helper T-cells.

> Gene Ontology
 
Biological Process GO:0000018 regulation of DNA recombination
GO:0001562 response to protozoan
GO:0001701 in utero embryonic development
GO:0001763 morphogenesis of a branching structure
GO:0001773 myeloid dendritic cell activation
GO:0001783 B cell apoptotic process
GO:0001818 negative regulation of cytokine production
GO:0001819 positive regulation of cytokine production
GO:0001889 liver development
GO:0001890 placenta development
GO:0001892 embryonic placenta development
GO:0002200 somatic diversification of immune receptors
GO:0002204 somatic recombination of immunoglobulin genes involved in immune response
GO:0002208 somatic diversification of immunoglobulins involved in immune response
GO:0002237 response to molecule of bacterial origin
GO:0002250 adaptive immune response
GO:0002263 cell activation involved in immune response
GO:0002274 myeloid leukocyte activation
GO:0002285 lymphocyte activation involved in immune response
GO:0002312 B cell activation involved in immune response
GO:0002366 leukocyte activation involved in immune response
GO:0002367 cytokine production involved in immune response
GO:0002374 cytokine secretion involved in immune response
GO:0002377 immunoglobulin production
GO:0002381 immunoglobulin production involved in immunoglobulin mediated immune response
GO:0002437 inflammatory response to antigenic stimulus
GO:0002439 chronic inflammatory response to antigenic stimulus
GO:0002440 production of molecular mediator of immune response
GO:0002443 leukocyte mediated immunity
GO:0002449 lymphocyte mediated immunity
GO:0002460 adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002521 leukocyte differentiation
GO:0002544 chronic inflammatory response
GO:0002562 somatic diversification of immune receptors via germline recombination within a single locus
GO:0002637 regulation of immunoglobulin production
GO:0002676 regulation of chronic inflammatory response
GO:0002677 negative regulation of chronic inflammatory response
GO:0002683 negative regulation of immune system process
GO:0002694 regulation of leukocyte activation
GO:0002695 negative regulation of leukocyte activation
GO:0002696 positive regulation of leukocyte activation
GO:0002697 regulation of immune effector process
GO:0002698 negative regulation of immune effector process
GO:0002700 regulation of production of molecular mediator of immune response
GO:0002701 negative regulation of production of molecular mediator of immune response
GO:0002703 regulation of leukocyte mediated immunity
GO:0002706 regulation of lymphocyte mediated immunity
GO:0002712 regulation of B cell mediated immunity
GO:0002718 regulation of cytokine production involved in immune response
GO:0002719 negative regulation of cytokine production involved in immune response
GO:0002739 regulation of cytokine secretion involved in immune response
GO:0002740 negative regulation of cytokine secretion involved in immune response
GO:0002819 regulation of adaptive immune response
GO:0002822 regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002861 regulation of inflammatory response to antigenic stimulus
GO:0002862 negative regulation of inflammatory response to antigenic stimulus
GO:0002874 regulation of chronic inflammatory response to antigenic stimulus
GO:0002875 negative regulation of chronic inflammatory response to antigenic stimulus
GO:0002889 regulation of immunoglobulin mediated immune response
GO:0002902 regulation of B cell apoptotic process
GO:0002904 positive regulation of B cell apoptotic process
GO:0006310 DNA recombination
GO:0006509 membrane protein ectodomain proteolysis
GO:0006606 protein import into nucleus
GO:0006809 nitric oxide biosynthetic process
GO:0006913 nucleocytoplasmic transport
GO:0007159 leukocyte cell-cell adhesion
GO:0007162 negative regulation of cell adhesion
GO:0007249 I-kappaB kinase/NF-kappaB signaling
GO:0007253 cytoplasmic sequestering of NF-kappaB
GO:0007259 JAK-STAT cascade
GO:0007346 regulation of mitotic cell cycle
GO:0007369 gastrulation
GO:0007568 aging
GO:0009306 protein secretion
GO:0009894 regulation of catabolic process
GO:0009895 negative regulation of catabolic process
GO:0010470 regulation of gastrulation
GO:0014823 response to activity
GO:0014854 response to inactivity
GO:0016064 immunoglobulin mediated immune response
GO:0016444 somatic cell DNA recombination
GO:0016445 somatic diversification of immunoglobulins
GO:0016447 somatic recombination of immunoglobulin gene segments
GO:0017038 protein import
GO:0019233 sensory perception of pain
GO:0019724 B cell mediated immunity
GO:0022407 regulation of cell-cell adhesion
GO:0022408 negative regulation of cell-cell adhesion
GO:0022409 positive regulation of cell-cell adhesion
GO:0030098 lymphocyte differentiation
GO:0030183 B cell differentiation
GO:0030595 leukocyte chemotaxis
GO:0030885 regulation of myeloid dendritic cell activation
GO:0030886 negative regulation of myeloid dendritic cell activation
GO:0030888 regulation of B cell proliferation
GO:0030889 negative regulation of B cell proliferation
GO:0031099 regeneration
GO:0031100 animal organ regeneration
GO:0031329 regulation of cellular catabolic process
GO:0031330 negative regulation of cellular catabolic process
GO:0031348 negative regulation of defense response
GO:0031503 protein complex localization
GO:0031644 regulation of neurological system process
GO:0031645 negative regulation of neurological system process
GO:0031960 response to corticosteroid
GO:0032091 negative regulation of protein binding
GO:0032102 negative regulation of response to external stimulus
GO:0032355 response to estradiol
GO:0032386 regulation of intracellular transport
GO:0032387 negative regulation of intracellular transport
GO:0032479 regulation of type I interferon production
GO:0032480 negative regulation of type I interferon production
GO:0032496 response to lipopolysaccharide
GO:0032507 maintenance of protein location in cell
GO:0032602 chemokine production
GO:0032606 type I interferon production
GO:0032607 interferon-alpha production
GO:0032609 interferon-gamma production
GO:0032612 interleukin-1 production
GO:0032615 interleukin-12 production
GO:0032621 interleukin-18 production
GO:0032635 interleukin-6 production
GO:0032637 interleukin-8 production
GO:0032640 tumor necrosis factor production
GO:0032642 regulation of chemokine production
GO:0032647 regulation of interferon-alpha production
GO:0032649 regulation of interferon-gamma production
GO:0032652 regulation of interleukin-1 production
GO:0032655 regulation of interleukin-12 production
GO:0032661 regulation of interleukin-18 production
GO:0032675 regulation of interleukin-6 production
GO:0032677 regulation of interleukin-8 production
GO:0032680 regulation of tumor necrosis factor production
GO:0032682 negative regulation of chemokine production
GO:0032687 negative regulation of interferon-alpha production
GO:0032689 negative regulation of interferon-gamma production
GO:0032692 negative regulation of interleukin-1 production
GO:0032695 negative regulation of interleukin-12 production
GO:0032701 negative regulation of interleukin-18 production
GO:0032715 negative regulation of interleukin-6 production
GO:0032717 negative regulation of interleukin-8 production
GO:0032720 negative regulation of tumor necrosis factor production
GO:0032800 receptor biosynthetic process
GO:0032868 response to insulin
GO:0032943 mononuclear cell proliferation
GO:0032944 regulation of mononuclear cell proliferation
GO:0032945 negative regulation of mononuclear cell proliferation
GO:0033002 muscle cell proliferation
GO:0033157 regulation of intracellular protein transport
GO:0033619 membrane protein proteolysis
GO:0034113 heterotypic cell-cell adhesion
GO:0034114 regulation of heterotypic cell-cell adhesion
GO:0034115 negative regulation of heterotypic cell-cell adhesion
GO:0034116 positive regulation of heterotypic cell-cell adhesion
GO:0034465 response to carbon monoxide
GO:0034504 protein localization to nucleus
GO:0035728 response to hepatocyte growth factor
GO:0035729 cellular response to hepatocyte growth factor stimulus
GO:0042035 regulation of cytokine biosynthetic process
GO:0042036 negative regulation of cytokine biosynthetic process
GO:0042089 cytokine biosynthetic process
GO:0042092 type 2 immune response
GO:0042098 T cell proliferation
GO:0042100 B cell proliferation
GO:0042107 cytokine metabolic process
GO:0042110 T cell activation
GO:0042113 B cell activation
GO:0042116 macrophage activation
GO:0042129 regulation of T cell proliferation
GO:0042130 negative regulation of T cell proliferation
GO:0042176 regulation of protein catabolic process
GO:0042177 negative regulation of protein catabolic process
GO:0042306 regulation of protein import into nucleus
GO:0042308 negative regulation of protein import into nucleus
GO:0042345 regulation of NF-kappaB import into nucleus
GO:0042347 negative regulation of NF-kappaB import into nucleus
GO:0042348 NF-kappaB import into nucleus
GO:0042493 response to drug
GO:0042533 tumor necrosis factor biosynthetic process
GO:0042534 regulation of tumor necrosis factor biosynthetic process
GO:0042536 negative regulation of tumor necrosis factor biosynthetic process
GO:0042742 defense response to bacterium
GO:0042832 defense response to protozoan
GO:0042990 regulation of transcription factor import into nucleus
GO:0042991 transcription factor import into nucleus
GO:0042992 negative regulation of transcription factor import into nucleus
GO:0042994 cytoplasmic sequestering of transcription factor
GO:0043030 regulation of macrophage activation
GO:0043032 positive regulation of macrophage activation
GO:0043112 receptor metabolic process
GO:0043122 regulation of I-kappaB kinase/NF-kappaB signaling
GO:0043124 negative regulation of I-kappaB kinase/NF-kappaB signaling
GO:0043393 regulation of protein binding
GO:0043434 response to peptide hormone
GO:0043900 regulation of multi-organism process
GO:0043901 negative regulation of multi-organism process
GO:0043903 regulation of symbiosis, encompassing mutualism through parasitism
GO:0044057 regulation of system process
GO:0044110 growth involved in symbiotic interaction
GO:0044116 growth of symbiont involved in interaction with host
GO:0044117 growth of symbiont in host
GO:0044126 regulation of growth of symbiont in host
GO:0044130 negative regulation of growth of symbiont in host
GO:0044144 modulation of growth of symbiont involved in interaction with host
GO:0044146 negative regulation of growth of symbiont involved in interaction with host
GO:0044744 protein targeting to nucleus
GO:0045019 negative regulation of nitric oxide biosynthetic process
GO:0045185 maintenance of protein location
GO:0045190 isotype switching
GO:0045191 regulation of isotype switching
GO:0045342 MHC class II biosynthetic process
GO:0045346 regulation of MHC class II biosynthetic process
GO:0045347 negative regulation of MHC class II biosynthetic process
GO:0045348 positive regulation of MHC class II biosynthetic process
GO:0045349 interferon-alpha biosynthetic process
GO:0045351 type I interferon biosynthetic process
GO:0045354 regulation of interferon-alpha biosynthetic process
GO:0045355 negative regulation of interferon-alpha biosynthetic process
GO:0045428 regulation of nitric oxide biosynthetic process
GO:0045785 positive regulation of cell adhesion
GO:0045786 negative regulation of cell cycle
GO:0045861 negative regulation of proteolysis
GO:0045926 negative regulation of growth
GO:0045930 negative regulation of mitotic cell cycle
GO:0045995 regulation of embryonic development
GO:0046209 nitric oxide metabolic process
GO:0046425 regulation of JAK-STAT cascade
GO:0046427 positive regulation of JAK-STAT cascade
GO:0046651 lymphocyte proliferation
GO:0046822 regulation of nucleocytoplasmic transport
GO:0046823 negative regulation of nucleocytoplasmic transport
GO:0048545 response to steroid hormone
GO:0048568 embryonic organ development
GO:0048608 reproductive structure development
GO:0048659 smooth muscle cell proliferation
GO:0048660 regulation of smooth muscle cell proliferation
GO:0048661 positive regulation of smooth muscle cell proliferation
GO:0048662 negative regulation of smooth muscle cell proliferation
GO:0048732 gland development
GO:0050663 cytokine secretion
GO:0050670 regulation of lymphocyte proliferation
GO:0050672 negative regulation of lymphocyte proliferation
GO:0050707 regulation of cytokine secretion
GO:0050708 regulation of protein secretion
GO:0050709 negative regulation of protein secretion
GO:0050710 negative regulation of cytokine secretion
GO:0050714 positive regulation of protein secretion
GO:0050715 positive regulation of cytokine secretion
GO:0050727 regulation of inflammatory response
GO:0050728 negative regulation of inflammatory response
GO:0050777 negative regulation of immune response
GO:0050803 regulation of synapse structure or activity
GO:0050807 regulation of synapse organization
GO:0050808 synapse organization
GO:0050863 regulation of T cell activation
GO:0050864 regulation of B cell activation
GO:0050865 regulation of cell activation
GO:0050866 negative regulation of cell activation
GO:0050867 positive regulation of cell activation
GO:0050868 negative regulation of T cell activation
GO:0050869 negative regulation of B cell activation
GO:0050900 leukocyte migration
GO:0051043 regulation of membrane protein ectodomain proteolysis
GO:0051045 negative regulation of membrane protein ectodomain proteolysis
GO:0051047 positive regulation of secretion
GO:0051048 negative regulation of secretion
GO:0051051 negative regulation of transport
GO:0051052 regulation of DNA metabolic process
GO:0051090 regulation of sequence-specific DNA binding transcription factor activity
GO:0051091 positive regulation of sequence-specific DNA binding transcription factor activity
GO:0051098 regulation of binding
GO:0051100 negative regulation of binding
GO:0051169 nuclear transport
GO:0051170 nuclear import
GO:0051220 cytoplasmic sequestering of protein
GO:0051222 positive regulation of protein transport
GO:0051224 negative regulation of protein transport
GO:0051235 maintenance of location
GO:0051249 regulation of lymphocyte activation
GO:0051250 negative regulation of lymphocyte activation
GO:0051384 response to glucocorticoid
GO:0051651 maintenance of location in cell
GO:0051930 regulation of sensory perception of pain
GO:0051931 regulation of sensory perception
GO:0060300 regulation of cytokine activity
GO:0060302 negative regulation of cytokine activity
GO:0060326 cell chemotaxis
GO:0060669 embryonic placenta morphogenesis
GO:0060670 branching involved in labyrinthine layer morphogenesis
GO:0060711 labyrinthine layer development
GO:0060713 labyrinthine layer morphogenesis
GO:0061008 hepaticobiliary system development
GO:0061138 morphogenesis of a branching epithelium
GO:0061458 reproductive system development
GO:0070227 lymphocyte apoptotic process
GO:0070228 regulation of lymphocyte apoptotic process
GO:0070230 positive regulation of lymphocyte apoptotic process
GO:0070486 leukocyte aggregation
GO:0070489 T cell aggregation
GO:0070586 cell-cell adhesion involved in gastrulation
GO:0070587 regulation of cell-cell adhesion involved in gastrulation
GO:0070661 leukocyte proliferation
GO:0070663 regulation of leukocyte proliferation
GO:0070664 negative regulation of leukocyte proliferation
GO:0071216 cellular response to biotic stimulus
GO:0071219 cellular response to molecule of bacterial origin
GO:0071222 cellular response to lipopolysaccharide
GO:0071392 cellular response to estradiol stimulus
GO:0071396 cellular response to lipid
GO:0071407 cellular response to organic cyclic compound
GO:0071593 lymphocyte aggregation
GO:0071609 chemokine (C-C motif) ligand 5 production
GO:0071649 regulation of chemokine (C-C motif) ligand 5 production
GO:0071650 negative regulation of chemokine (C-C motif) ligand 5 production
GO:0071706 tumor necrosis factor superfamily cytokine production
GO:0071887 leukocyte apoptotic process
GO:0072577 endothelial cell apoptotic process
GO:0072593 reactive oxygen species metabolic process
GO:0090317 negative regulation of intracellular protein transport
GO:0097421 liver regeneration
GO:0097696 STAT cascade
GO:0098542 defense response to other organism
GO:0098742 cell-cell adhesion via plasma-membrane adhesion molecules
GO:1900120 regulation of receptor binding
GO:1900121 negative regulation of receptor binding
GO:1900180 regulation of protein localization to nucleus
GO:1900181 negative regulation of protein localization to nucleus
GO:1901652 response to peptide
GO:1902532 negative regulation of intracellular signal transduction
GO:1902593 single-organism nuclear import
GO:1903034 regulation of response to wounding
GO:1903037 regulation of leukocyte cell-cell adhesion
GO:1903038 negative regulation of leukocyte cell-cell adhesion
GO:1903409 reactive oxygen species biosynthetic process
GO:1903426 regulation of reactive oxygen species biosynthetic process
GO:1903427 negative regulation of reactive oxygen species biosynthetic process
GO:1903531 negative regulation of secretion by cell
GO:1903532 positive regulation of secretion by cell
GO:1903533 regulation of protein targeting
GO:1903555 regulation of tumor necrosis factor superfamily cytokine production
GO:1903556 negative regulation of tumor necrosis factor superfamily cytokine production
GO:1903828 negative regulation of cellular protein localization
GO:1904019 epithelial cell apoptotic process
GO:1904057 negative regulation of sensory perception of pain
GO:1904406 negative regulation of nitric oxide metabolic process
GO:1904589 regulation of protein import
GO:1904590 negative regulation of protein import
GO:1904705 regulation of vascular smooth muscle cell proliferation
GO:1904706 negative regulation of vascular smooth muscle cell proliferation
GO:1904707 positive regulation of vascular smooth muscle cell proliferation
GO:1904892 regulation of STAT cascade
GO:1904894 positive regulation of STAT cascade
GO:1904950 negative regulation of establishment of protein localization
GO:1904951 positive regulation of establishment of protein localization
GO:1990874 vascular smooth muscle cell proliferation
GO:2000106 regulation of leukocyte apoptotic process
GO:2000108 positive regulation of leukocyte apoptotic process
GO:2000377 regulation of reactive oxygen species metabolic process
GO:2000378 negative regulation of reactive oxygen species metabolic process
GO:2001057 reactive nitrogen species metabolic process
Molecular Function GO:0005125 cytokine activity
GO:0005126 cytokine receptor binding
GO:0005141 interleukin-10 receptor binding
GO:0008083 growth factor activity
GO:0070851 growth factor receptor binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04060 Cytokine-cytokine receptor interaction
hsa04068 FoxO signaling pathway
hsa04630 Jak-STAT signaling pathway
hsa04660 T cell receptor signaling pathway
hsa04672 Intestinal immune network for IgA production
Reactome R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-168256: Immune System
R-HSA-6783783: Interleukin-10 signaling
R-HSA-6785807: Interleukin-4 and 13 signaling
R-HSA-449147: Signaling by Interleukins
Summary
SymbolIL10
Nameinterleukin 10
Aliases CSIF; IL10A; IL-10; cytokine synthesis inhibitory factor; T-cell growth inhibitory factor; GVHDS; IL-10A; In ......
Chromosomal Location1q31-q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between IL10 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between IL10 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
28249894Plasma Cell MyelomaInhibit immunity (T cell function)We study CD38 levels in immunosuppressive CD4+CD25highFoxp3+regulatory T cells (Treg) and further define immunomodulating effects of a therapeutic CD38 mAb isatuximab/SAR650984 in multiple myeloma. Isatuximab reduces Foxp3 and IL10 in Tregs and restores proliferation and function of Tcons.
28212885Myeloid NeoplasmInhibit immunity (T cell function)Human macrophages exposed to epinephrine and TNFα, or macrophages generated in 6day cultures in the presence of epinephrine, expressed high levels of COX-2, IDO and IL-10, and strongly suppressed both the proliferation and IFNγ production of CD8+T cells.
26740106Head and Neck Squamous Cell CarcinomaInhibit immunity (T cell function)Similarly, knockdown of Sema4D in an HNSCC cell line resulted in a loss of MDSC function as shown by a decrease in the production of the immune-suppressive cytokines arginase-1, TGF-β, and IL-10 by MDSC, concomitant with recovery of T cell proliferation and IFN-γ production following stimulation of CD3/CD28.
27001312GliomaInhibit immunity (T cell function)Mechanistically, glioma initiating CD133(+) cells and Mφs/microglia cointeraction activated expression of B7-H4 via IL6 and IL10 in both tumor cells and microenvironment supporting cells. IL6-activated STAT3 bound to the promoter of B7-H4 gene and enhanced B7-H4 expression. Furthermore, CD133(+) cells mediated immunosuppression through B7-H4 expression on Mφs/microglia by silencing of B7-H4 expression on these cells, which led to increased microenvironment T-cell function and tumor regression in the xenograft glioma mouse model.
26994345Breast CarcinomaInhibit immunityThe delivery of let-7b could reactivate TAMs/TIDCs by acting as a TLR-7 agonist and suppressing IL-10 production in vitro. In a breast cancer mouse model, let-7b delivered by this system efficiently reprogrammed the functions of TAMs/TIDCs, reversed the suppressive tumor microenvironment, and inhibited tumor growth.
26928313Hepatocellular CarcinomaInhibit immunity (T cell function)TLR4-mediated BCL6 upregulation was crucial for PD-1(hi) B-cell induction by HCC environmental factors, and that effect was abolished by IL4-elicited STAT6 phosphorylation. Importantly, upon encountering PD-L1(+) cells or undergoing PD-1 triggering, PD-1(hi) B cells acquired regulatory functions that suppressed tumor-specific T-cell immunity and promoted cancer growth via IL10 signals.
26880715Lung CarcinomaInhibit immunity (T cell function)Overexpression of the mutant KRAS(G12V)gene in wild-type KRAS tumor cells led to regulatory T-cell (Treg) induction. We also demonstrate that mutant KRAS induces the secretion of IL10 and transforming growth factor-β1 (both required for Treg induction) by tumor cells through the activation of the MEK-ERK-AP1 pathway.
25944800MelanomaInhibit immunity (T cell function)Functional studies demonstrated that some factors, including IL10 and IL32-gamma, induced PD-L1 expression on monocytes but not tumor cells.
25924065Prostate CarcinomaInhibit immunity (T cell function)The crucial immunosuppressive B cells are plasmocytes that express IgA, interleukin (IL)-10 and programmed death ligand 1 (PD-L1), the appearance of which depends on TGFβ receptor signalling. Elimination of these cells, which also infiltrate human-therapy-resistant prostate cancer, allows CTL-dependent eradication of oxaliplatin-treated tumours.
25744203GlioblastomaInhibit immunity (T cell function)Taken together, these results suggest that glioblastoma may cooperate with Treg cells via OX40L, thereby enhancing IL-10 production. IL-10 in turn generates the immunosuppressive microenvironment. Such pro-tumor effects caused by Treg cells may be enhanced under hypoxic conditions.
25720800MelanomaInhibit immunity (T cell function)IL10 and PD-1 Cooperate to Limit the Activity of Tumor-Specific CD8+ T Cells. Collectively, our findings offer a rationale to block both IL10 and PD-1 to strengthen the counteraction of T-cell immunosuppression and to enhance the activity of TA-specific CD8(+) T cell in advanced melanoma patients.
25614966MelanomaInhibit immunity (T cell function)Thus, our data identify an IL-27/NFIL3 signalling axis as a key regulator of effector T-cell responses via induction of Tim-3, IL-10 and T-cell dysfunction.
25545618Breast CarcinomaInhibit immunity (T cell function)Depletion of IL-10 in B-cell adoptive transfers significantly increased CTLs and B-cell activity of PBMCs
25363661GlioblastomaInhibit immunityWhile a number of key immunosuppressive cytokines were overexpressed in the treated cells, including IL-10, IL-6 and GM-CSF, suppression could be alleviated in a number of treated GBM lines by inhibition of prostaglandin E2.
25261236Breast CarcinomaInhibit immunityIn this study, we show that DCs isolated from patients with metastatic or locally advanced breast cancer express high levels of the adiponectin receptors AdipoR1 and AdipoR2, which are sufficient to blunt antitumor immunity. AdipoR1 stimulated IL10 production by activating the AMPK and MAPKp38 pathways, whereas AdipoR2 modified inflammatory processes by activating the COX-2 and PPARγ pathways.
22581824Squamous Cell CarcinomaPromote immunity (T cell function)Together, our findings indicate that IL-10 activates CD8(+) T-cell-mediated tumor control and suggest that IL-10 may represent a potential tumor immunotherapy in human patients with cancer.
29379494Chronic Lymphocytic LeukemiaInhibit immunityThe CXCR4-STAT3-IL-10 Pathway Controls the Immunoregulatory Function of Chronic Lymphocytic Leukemia and Is Modulated by Lenalidomide. Lenalidomide also suppressed IL-10-induced Y705-STAT3 phosphorylation in healthy T cells, thus reversing CLL-induced T-cell dysfunction.
29379494Chronic Lymphocytic LeukemiaInhibit immunity (T cell function); immunotherapy targetHere, we show that the CXC chemokine ligand 12 (CXCL12)-CXCR4-STAT3 axis regulates IL-10 production by CLL cells and their ability to suppress T-cell effector function through an IL-10 mediated mechanism. We conclude that the capacity of CLL cells to produce IL-10 is mediated by the CXCL12-CXCR4-STAT3 pathway and likely contributes to immunodeficiency in patients. Lenalidomide also suppressed IL-10-induced Y705-STAT3 phosphorylation in healthy T cells, thus reversing CLL-induced T-cell dysfunction.
18381452Breast CarcinomaInhibit immunityInterestingly, the tumor tolerance model instead displayed immune suppression pathways through activation of regulatory mechanisms that included in particular the overexpression of interleukin-10 (IL-10), IL-10 receptor, and suppressor of cytokine signaling (SOCS)-1 and SOCS-3.
27297552Melanoma; Lung carcinoma; Breast carcinoma; liver carcinomaPromote immunityIn contrast to its inhibitory effects on many cells, IL10 activates CD8(+) tumor-infiltrating lymphocytes (TIL) and enhances their antitumor activity. However, CD8(+) TILs do not routinely express IL10, as autocrine complement C3 inhibits IL10 production through complement receptors C3aR and C5aR. CD8(+) TILs from C3-deficient mice, however, express IL10 and exhibit enhanced effector function.
19427884NeuroblastomaInhibit immunityInterleukin 10 (IL-10) suppresses antigen presenting cell activation contributing to tumour-mediated immune suppression. In principle, combination of TL-asCpG and antibodies against IL-10 receptor (aIL-10R) could prolong immune system activation, leading to better therapeutic results.
28442553Pancreatic CarcinomaInhibit immunity (T cell function)NLRP3 signaling drives macrophage-induced adaptive immune suppression in pancreatic carcinoma. The suppressive effects of NLRP3 signaling were IL-10 dependent.
23613317GliomaInhibit immunity (T cell function)Stimulation of monocytes with IL-10 alone could significantly increase B7-H1 expression, sufficient to induce T-cell apoptosis when cocultured with stimulated monocytes. Gliomas can upregulate B7-H1 expression in circulating monocytes and tumor-infiltrative macrophages through modulation of autocrine/paracrine IL-10 signaling, resulting in an immunosuppressive phenotype.
22566819Ovarian CarcinomaInhibit immunity (T cell function)Here we identify a novel pathway in which the tumor-infiltrating MDSC are the predominant producers of IL-10 and, importantly, require it to develop their immunosuppressive function in vivo. Importantly, we demonstrate that the role of IL-10 is critical, and not redundant with other immunosuppressive molecules, to in vivo tumor progression: blockade of the IL-10 signaling network results in alleviation of MDSC-mediated immunosuppression, altered T cell phenotype and activity, and improved survival.
21191065Lung CarcinomaInhibit immunity (T cell function)We have shown that galectin-1 is highly expressed in lung cancer cell lines, together with the serum and surgical samples from lung cancer patients. Functionally, lung cancer-derived galectin-1 has been shown to alter the phenotypes of monocyte-derived DCs (MdDCs) and impair alloreactive T cell response, concomitant with the increase of CD4(+)CD25(+)FOXP3(+) regulatory T cells. The regulatory effect of galectin-1 is mediated, in part, through its ability to induce, in an Id3 (inhibitor of DNA binding 3)-dependent manner, the expression of IL-10 in monocytes and MdDCs. Of note, significant upregulation of IL-10 was seen in tumor-infiltrating CD11c(+) DCs in human lung cancer samples.
21178005Choriocarcinoma; Breast Carcinoma; Ovarian CarcinomaInhibit immunityTumor-associated a2 vacuolar ATPase acts as a key mediator of cancer-related inflammation by inducing pro-tumorigenic properties in monocytes. These included IL-1β and IL-10, which are important in promoting inflammation and immune escape by tumor cells.
21159663MelanomaInhibit immunityInduction of monocyte chemoattractant protein-1 and interleukin-10 by TGFbeta1 in melanoma enhances tumor infiltration and immunosuppression.
21159663MelanomaInhibit immunityInduction of monocyte chemoattractant protein-1 and interleukin-10 by TGFbeta1 in melanoma enhances tumor infiltration and immunosuppression. Supernatants from TGFβ1-treated A375 cells enhanced MCP-1-dependent migration of monocytes, which, in turn, expressed high levels of TGF,β1, bFGF, and VEGF mRNA. Moreover, these supernatants also inhibited functional properties of dendritic cells through IL-10-dependent mechanisms.
21078911Colon CarcinomaInhibit immunity (T cell function)In this tumoral environment, these monocytes can differentiate into tolerogenic dendritic cells (DCs) that produce IL-10 and potently induce regulatory T cell responses in vivo. Moreover, diverting the differentiation of Gr-1(+) monocytes into tolerogenic DCs by forced expression of IL-10 soluble receptor and IL-3 in tumor cells improves host immunosurveillance by reducing the regulatory T cell frequency and by inducing immunogenic DCs in the tumor.
19549770MelanomaInhibit immunity (T cell function)DCs from melanoma-bearing mice secreted significantly more interleukin 10 and less interleukin 12p70, and showed a decreased capacity to activate T cells compared with DCs from tumor-free animals.
19549768Cervical CarcinomaInhibit immunity (T cell function)We used the HPV16 E6- and E7-expressing TC-1 mouse tumor model to study the effect of TAM on T-cell function in vitro, and depleted TAM, using clodronate-containing liposomes, to characterize its role in vivo. TAM displayed high basal Arginase I activity, producing interleukin-10 (IL-10); they were resistant to iNOSII activity induction, therefore reversion to M1 phenotype, when stimulated in vitro with lipopolysaccharide/IFNgamma, indicating an M2 phentoype. In cultures of isolated TAM, TAM induced regulatory phenotype, characterized by IL-10 and Foxp3 expression, and inhibited proliferation of CD8 lymphocytes.
19494278Colon Carcinoma; Prostate CarcinomaInhibit immunityPGDH-mediated antitumor effect was associated with attenuated tumor-induced immune suppression and substantially reduced secretion of immunosuppressive mediators and cytokines such as PGE(2), IL-10, IL-13, and IL-6 by intratumoral CD11b cells. We show also that introduction of 15-PGDH gene in tumor tissue is sufficient to redirect the differentiation of intratumoral CD11b cells from immunosuppressive M2-oriented F4/80(+) tumor-associated macrophages (TAM) into M1-oriented CD11c(+) MHC class II-positive myeloid APCs.
29034589Colon CarcinomaInhibit immunity (T cell function)Giving angiotensin II receptor blockers (ARB) to C57BL/6 mice bearing murine colon cancer cell line MC38 resulted in significant enhancement of tumor antigen gp70 specific T cells. ARB administration did not change the numbers of CD11b+ myeloid cells in tumors, but significantly reduced their T-cell inhibitory ability along with decreased production of various immunosuppressive factors including interleukin (IL)-6, IL-10, vascular endothelial growth factor (VEGF), and arginase by CD11b+ cells in tumors.
28868628Ovarian CarcinomaInhibit immunity (T cell function)Ovarian cancer stem cells promote tumour immune privilege and invasion via CCL5 and regulatory T cells. The expression of its receptor, C-C motif chemokine receptor 5 (CCR5), was also increased on the surface of Tregs in ovarian cancer patients. This receptor-ligand expression profile indicated that ovarian CSCs recruit Tregs via CCL5-CCR5 interactions. Tregs cultured in conditioned medium (CM) from ovarian CD133+ cells expressed a higher level of IL-10 than Tregs cultured in CM from CD133- cells, indicating that Tregs exert pronounced immune-inhibitory functions in CSC-rich environments.
16751376Breast CarcinomaInhibit immunity (T cell function)A single intratumoral injection of IL-12 and GM-CSF-encapsulated microspheres induces the complete regression of advanced spontaneous tumors in her-2/neu transgenic mice. Posttherapy molecular analysis of immune activation/suppression markers within the tumor microenvironment demonstrated a dramatic up-regulation of IFN-gamma and a concomitant down-regulation of Forkhead/winged-helix protein 3 (Foxp3), TGFbeta, and IL-10 expression.
16540672Lung CarcinomaInhibit immunityA single intratracheal administration of CCL21 gene-modified dendritic cells (DC-AdCCL21) led to a marked reduction in tumor burden with extensive mononuclear cell infiltration of the tumors. The reduction in tumor burden was accompanied by the enhanced elaboration of type 1 cytokines [IFN-gamma, interleukin (IL)-12, and granulocyte macrophage colony-stimulating factor] and antiangiogenic chemokines (CXCL9 and CXCL10) but a concomitant decrease in the immunosuppressive molecules (IL-10, transforming growth factor-beta, prostaglandin E(2)) in the tumor microenvironment. The DC-AdCCL21 therapy group revealed a significantly greater frequency of tumor-specific T cells releasing IFN-gamma compared with the controls.
24793239Ovarian CarcinomaInhibit immunity (infiltration and cell function)In these tumors, FasL expression was associated with scarce CD8(+) infiltration and a predominance of FoxP3(+) T regulatory (Treg) cells. Tumor-derived vascular endothelial growth factor A (VEGF-A), interleukin 10 (IL-10) and prostaglandin E2 (PGE2) cooperatively induced FasL expression in endothelial cells, which acquired the ability to kill effector CD8(+) T cells but not Treg cells because of higher levels of c-FLIP expression in Treg cells. In mice, genetic or pharmacologic suppression of FasL produced a substantial increase in the influx of tumor-rejecting CD8(+) over FoxP3(+) T cells. Pharmacologic inhibition of VEGF and PGE2 produced a marked increase in the influx of tumor-rejecting CD8(+) over FoxP3(+) T cells that was dependent on attenuation of FasL expression and led to CD8-dependent tumor growth suppression.
24778419Melanoma; Lung Carcinoma; Colon Carcinoma; Breast CarcinomaInhibit immunity (T cell function)Finally, neutralizing antibodies against IL-10 under hypoxia significantly abrogated the suppressive activity of MDSCs.
20714339ErythroleukemiaInhibit immunity (T cell function)MICA mRNA levels decreased in IL-10-treated FMS and IL-10-transduced BL cell lines. Interestingly, we observed that MICB surface expression and its mRNA levels increased upon IL-10 treatment in a melanoma cell line. These changes in NKG2D ligands surface expression patterns owing to IL-10 treatment resulted in an effect on lysis susceptibility mediated by lymphocyte-activated killer cells, as tumour cell lines that displayed a higher decrease of MICA on their surface had lower levels of lysis.
17947638Hepatocellular CarcinomaInhibit immunity (T cell function)We demonstrate here that DCs devoid of IL-10, a potent immunosuppressive cytokine, are superior over conventional DCs in triggering antitumor immunity. The IL-10(-/-)DCs were highly immunogenic, expressed enhanced levels of surface MHC class II molecules, and secreted increased amounts of Th1-related cytokines.
17709502B Acute Lymphoblastic LeukemiaInhibit immunity (T cell function)Here, we report that B-ALL CD23+CD5+ B cells produce IL-10 at high level, which can be further elevated by costimulation with CCL19 and CXCL13. CCL19/CXCL13-activated B-ALL CD23+CD5+ B cells, in turn, increase IL-10 expression in syngeneic CD8+ T cells in a B cell-derived IL-10-dependent manner and requiring a cell-cell contact. IL-10 secreted from B-ALL CD23+CD5+ B cells in vitro impairs tumor-specific CTL responses of syngeneic CD8+ T cells.
27853178Hepatocellular CarcinomaInhibit immunity (T cell function)More importantly, the activated FcγRIIlow/- B cells from HCC tumours, but not the resting FcγRIIhigh B cells, without external stimulation suppress autologous tumour-specific cytotoxic T-cell immunity via IL-10 signals.
23960017Hepatocellular CarcinomaInhibit immunity (T cell function)Human CD14+ CTLA-4+ regulatory dendritic cells suppress T-cell response by cytotoxic T-lymphocyte antigen-4-dependent IL-10 and indoleamine-2,3-dioxygenase production in hepatocellular carcinoma. CD14(+) DCs significantly suppress T-cell response in vitro through interleukin (IL)-10 and indoleamine-2,3-dioxygenase (IDO). Unexpectedly, CD14(+) DCs expressed high levels of cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death-1, and CTLA-4 was found to be essential to IL-10 and IDO production. So, we identified a novel human tumor-induced regulatory DC subset, which suppresses antitumor immune response through CTLA-4-dependent IL-10 and IDO production, thus indicating the important role of nonregulatory T-cell-derived CTLA-4 in tumor-immune escape or immunosuppression.
23861541Nasopharyngeal CarcinomaInhibit immunityAn increase in C/EBPδ abundance in macrophages in response to PGE? resulted in enhanced production of the immunosuppressive cytokine interleukin-10 (IL-10) and of pentraxin 3 (PTX3), which suppresses the ability of macrophages to phagocytose tumor cells.
21515097Colorectal CancinomaInhibit immunityIn addition, Cy + AdIL-12 modified Tregs functionality by inhibiting the in vitro secretion of IL-10 and TGF-β and their ability to inhibit dendritic cells activation. Combined treatment decreased the number of myeloid-derived suppressor cells (MDSCs) in comparison to non-treated mice and, interestingly, administration of Tregs restored splenic MDSCs population.
20144842Ovarian CancinomaInhibit immunityBesides the immune-activating tumor infiltrating lymphocytes (TILs), immune-suppressive regulatory T-cells (Tregs), tolerance-inducing plasmacytoid dendritic cells (pDCs), B7-H4+ macrophages, immune-suppressive cytokines such as IL10 and TGF-beta are also found in the tumor environment.
20013807Gastrointestinal Stromal TumorInhibit immunityHowever, imatinib and sunitinib did induce secretion of anti-inflammatory IL-10 in macrophage cultures, indicating that treatment with these inhibitors might contribute to an immune suppressive microenvironment in GIST.
20008791Acute Myeloid LeukemiaInhibit immunityBidirectional signaling following CD137-CD137L interaction induced the release of the immunomodulatory cytokines interleukin-10 and TNF by AML cells and directly diminished granule mobilization, cytotoxicity, and interferon-gamma production of human NK cells, which was restored by blocking CD137.
29336814Pancreatic CarcinomaInhibit immunityInhibition of Interleukin-10 in the tumor microenvironment can restore mesothelin chimeric antigen receptor T cell activity in pancreatic cancer in vitro. Pancreatic cancer cells are known to shield themselves from immunosurveillance by secreting immune inhibitory cytokines such as Interleukin-10. Substantial reversal of tumor-derived immunosuppression may be achieved by blocking Interleukin-10 in the local microenvironment, allowing for more effective cytotoxicity of mesothelin-engrafted chimeric antigen receptor T cells and enhancing the potential for clinical application.
18559587Head and Neck Squamous Cell CarcinomaInhibit immunity (T cell function)Tr1 cells suppressed proliferation of autologous responders via IL-10 and TGF-beta1 secretion. In HNSCC, Tr1 cell generation is promoted at the tumor site. Tr1 cells use TGF-beta and IL-10 to mediate suppression.
24216477Colon CarcinomaInhibit immunityThe capacity of IL-10 and Tregs in the inflammatory tumor microenvironment to impair anticancer Th1 immunity makes them attractive targets for cancer immunotherapy. IL-10 production limited Th17 cell numbers in both spleen and tumor.
22172723Skin Squamous Cell CarcinomaPromote immunityDefying those expectations we demonstrate that IL-10 induces several essential mechanisms for effective antitumor immune surveillance: infiltration and activation of intratumoral tumor-specific cytotoxic CD8(+) T cells, expression of the Th1 cytokine interferon-γ (IFNγ) and granzymes in CD8(+) T cells, and intratumoral antigen presentation molecules. Consequently, tumor immune surveillance is weakened in mice deficient for IL-10 whereas transgenic overexpression of IL-10 protects mice from carcinogenesis.
22019587Non-Hodgkin LymphomaInhibit immunity; Resistant to immunotherapyRegulatory B cell production of IL-10 inhibits lymphoma depletion during CD20 immunotherapy in mice. Even small numbers of adoptively transferred B10 cells dramatically suppressed CD20 mAb-mediated lymphoma depletion by inhibiting mAb-mediated monocyte activation and effector function through IL-10-dependent mechanisms.
20675592Hepatocellular CarcinomaInhibit immunityThe apoptosis-inducing capacity was determined by higher expression levels of arginase I and IL-10 relative to those of NO synthase 2 and IL-12 in Gr-1(+)CD11b(+)F4/80(+) cells, which were induced by NTC-Ms through TLR4 signaling. The apoptosis-inducing capacity of NTC-Ms-stimulated Gr-1(+)CD11b(+)F4/80(+) cells could be enhanced by IL-10.
20662098Plasmacytoma; MastocytomaInhibit immunity; Resistant to immunotherapyNeutralization of IL-10 significantly inhibited the suppressor activity of TAMC, and IL-10-deficiency allowed TAMC to kill cancer cells and their antigenic variants, which prevented tumor recurrence during CTL therapy.
20308630Breast CarcinomaInhibit immunity; Resistant to immunotherapyBlockade of IL-10, but not TGF-beta, enhanced the antitumor effect of imiquimod by significantly prolonging survival in treated mice. These data suggest that the excessive inflammation induced by TLR agonists may result in a self-regulatory immunosuppression via IL-10 induction and that blocking IL-10 could enhance the therapeutic efficacy of these agents.
29872577Lung CarcinomaPromote immunityRemarkably, TAMs secrete the known T-cell suppressive cytokine interleukin-10 (IL-10) to activate, but not to repress, CTLs.
29712773Chronic Lymphocytic LeukemiaInhibit immunityIn IL-10R-/- mice, wherein the host immune cells are unresponsive to IL-10-mediated suppressive effects, there was a significant reduction in CLL cell growth compared with wild type mice. IL-10 reduced the generation of effector CD4 and CD8 T cells.
17579057Malignant Skin NeoplasmInhibit immunityIL-10 has been shown to be a key mediator of UV-induced immunosuppression. IL-10(+/+) and IL-10(+/-) mice developed skin cancer to similar extents, whereas IL-10(-/-) mice were protected against the induction of skin malignancies by UV. Together, these findings indicate that IL-10 is critically involved in antitumoral immunity during photocarcinogenesis.
25223704lung carcinomaInhibit immunity(T cell function)These results suggest that IL-10 might be involved in the suppression of the immune system by Tregs induced by tumor-secreted miR-214
25187059breast carcinomaInhibit immunity (T cell function)Targeting involution with a neutralizing antibody against the immunosuppressive cytokine IL-10 reduces tumor growth in involution group mice but not in nulliparous mice, implicating the involution microenvironment as the primary target of aIL-10 treatment
25170116breast carcinoma; colon carcinomaInhibit immunityMDSC and macrophage cross-talk enhances IL-10 production while IL-10 decreases antigen presentation, immune activation, and tumor cell destruction
17617589breast carcinomaInhibit immunityTreatment with the chemotherapeutic drug gemcitabine, which reduces MDSC, promotes rejection of established metastatic disease in IL-4Ralpha(-/-) mice that produce M1 macrophages by allowing T cell activation, by maintaining macrophage production of IL-12, and by preventing increased production of IL-10
25164013breast carcinoma; colon carcinoma; melanoma; colon adenocarcinoma; prostate carcinomaInhibit immunityFurthermore, HMGB1 increased MDSC-mediated production of IL-10, enhanced crosstalk between MDSCs and macrophages, and facilitated the ability of MDSCs to downregulate expression of the T-cell homing receptor L-selectin
23384943Pan-CancerInhibit immunityMechanistic investigations into how IL-21 induced GrB expression in B cells to confer Breg function revealed a CD19?CD38?CD1d?IgM?CD147? expression signature, along with expression of additional key regulatory molecules including IL-10, CD25, and indoleamine-2,3-dioxygenase
23262246Hepatocellular CarcinomaInhibit immunityThe functional impairment of HCC-infiltrating γδ T cells, partially mediated by regulatory T cells in a TGFβ- and IL-10-dependent manner.
23225163plasmacytomaPromote immunityWhile STAT3 activation and the CTL survival-enhancing effects can be independent of CTL IL-10 production, we show here that IL-27-induced CTL IL-10 production contributes to memory precursor cell phenotype induction, CTL memory, and tumor rejection.
21900394renal cell carcinomaInhibit immunityInhibition of lipoxygenase activity significantly reduced production of CCL2 and IL-10 by RCC TAMs. In addition, TAMs isolated from RCC were capable of inducing in T lymphocytes, the pivotal T regulatory cell transcription factor forkhead box P3 (FOXP3), and the inhibitory cytotoxic T-lymphocyte antigen 4 (CTLA-4) coreceptor.
21784871Breast CarcinomaInhibit immunityFurthermore, we showed that treatment with these NPs resulted in priming of the immune TME, characterized by increased IFN-gamma, p-STAT-1, GM-CSF, IL-2, IL-15, and IL-12b and reduced TGF-beta, IL-6, and IL-10 protein expression. In addition, we found significantly increased tumor infiltration by activated CD8(+) T cells, M1 macrophages, and dendritic cells.
16885333colon carcinomaInhibit immunityThese data suggest that infections with enteric pathogens enhance T(R)-cell potency and protect against epithelial cancers later in life, potentially explaining paradoxical increases in cancer risk in developed countries having more stringent hygiene practices. The mammary and intestinal tumor development as well as the increase in proinflammatory mediators is suppressed by adoptive transfer of interleukin 10-competent CD4+CD45RB(lo)CD25+ regulatory (T(R)) cells.
16818744colon carcinomaInhibit immunityThese findings suggest that tumor growth facilitates the induction or recruitment of CD4+ regulatory T cells that secrete IL-10 and TGF-beta and suppress effector CD8+ T cell responses. However, CD8+ T regulatory cells expressing IL-10 and TGF-beta are also recruited or activated by the immunosuppressive environment of the lung, where they may suppress the induction of antitumor immunity.
16801397MelanomaInhibit immunityHere, we demonstrate a novel role of the activated MAPK pathway in immune evasion by melanoma cells with the mutation of BRAF, which encodes a MAPKKs, (BRAF(V600E)). MEK inhibitor U0126 or RNA interference (RNAi) for BRAF(V600E) decreased production of the immunosuppressive soluble factors interleukin (IL)-10, VEGF, or IL-6 from melanoma cells to levels comparable to those after signal transducer and activator of transcription (STAT)3 inactivation
Summary
SymbolIL10
Nameinterleukin 10
Aliases CSIF; IL10A; IL-10; cytokine synthesis inhibitory factor; T-cell growth inhibitory factor; GVHDS; IL-10A; In ......
Chromosomal Location1q31-q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of IL10 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolIL10
Nameinterleukin 10
Aliases CSIF; IL10A; IL-10; cytokine synthesis inhibitory factor; T-cell growth inhibitory factor; GVHDS; IL-10A; In ......
Chromosomal Location1q31-q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of IL10 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.7910.00533
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.9180.101
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.6980.133
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.6040.241
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.8950.322
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.2270.845
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.340.581
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.0190.984
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.6450.499
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.230.812
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.7340.568
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.1050.624
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of IL10 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolIL10
Nameinterleukin 10
Aliases CSIF; IL10A; IL-10; cytokine synthesis inhibitory factor; T-cell growth inhibitory factor; GVHDS; IL-10A; In ......
Chromosomal Location1q31-q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of IL10. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolIL10
Nameinterleukin 10
Aliases CSIF; IL10A; IL-10; cytokine synthesis inhibitory factor; T-cell growth inhibitory factor; GVHDS; IL-10A; In ......
Chromosomal Location1q31-q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of IL10. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by IL10.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolIL10
Nameinterleukin 10
Aliases CSIF; IL10A; IL-10; cytokine synthesis inhibitory factor; T-cell growth inhibitory factor; GVHDS; IL-10A; In ......
Chromosomal Location1q31-q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of IL10. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolIL10
Nameinterleukin 10
Aliases CSIF; IL10A; IL-10; cytokine synthesis inhibitory factor; T-cell growth inhibitory factor; GVHDS; IL-10A; In ......
Chromosomal Location1q31-q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of IL10 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolIL10
Nameinterleukin 10
Aliases CSIF; IL10A; IL-10; cytokine synthesis inhibitory factor; T-cell growth inhibitory factor; GVHDS; IL-10A; In ......
Chromosomal Location1q31-q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between IL10 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolIL10
Nameinterleukin 10
Aliases CSIF; IL10A; IL-10; cytokine synthesis inhibitory factor; T-cell growth inhibitory factor; GVHDS; IL-10A; In ......
Chromosomal Location1q31-q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting IL10 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting IL10.
ID Name Drug Type Targets #Targets
DB05744CRx-139Small MoleculeCRP, IL10, IL6, TNF4
DB05771LLL-3348Small MoleculeIL101